Bank of New York Mellon
RVMD icon

Bank of New York Mellon’s Revolution Medicines RVMD Stock Holding History

Bank of New York Mellon’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113M Sell
601,056
-34,310
-5% -$5.01M 0.02% 612
2026
Q1 		$61.8M Buy
635,366
+93,297
+17% +$9.42M 0.01% 871
2025
Q4 		$43.2M Buy
542,069
+12,799
+2% +$839K 0.01% 1092
2025
Q3 		$24.7M Buy
529,270
+34,657
+7% +$1.36M ﹤0.01% 1427
2025
Q2 		$18.2M Sell
494,613
-88,108
-15% -$3.38M ﹤0.01% 1569
2025
Q1 		$20.6M Buy
582,721
+13,706
+2% +$556K ﹤0.01% 1486
2024
Q4 		$24.9M Buy
569,015
+36,705
+7% +$1.85M ﹤0.01% 1442
2024
Q3 		$24.1M Sell
532,310
-112,943
-18% -$4.92M ﹤0.01% 1466
2024
Q2 		$25M Buy
645,253
+115,844
+22% +$4.33M ﹤0.01% 1444
2024
Q1 		$17.1M Sell
529,409
-51,807
-9% -$1.54M ﹤0.01% 1664
2023
Q4 		$16.7M Buy
581,216
+160,850
+38% +$3.87M ﹤0.01% 1694
2023
Q3 		$11.6M Buy
420,366
+8,825
+2% +$262K ﹤0.01% 1858
2023
Q2 		$11M Buy
411,541
+118,930
+41% +$2.92M ﹤0.01% 1906
2023
Q1 		$6.34M Buy
292,611
+33,343
+13% +$821K ﹤0.01% 2168
2022
Q4 		$6.18M Buy
259,268
+1,403
+0.5% +$29.8K ﹤0.01% 2209
2022
Q3 		$5.08M Buy
257,865
+59,854
+30% +$1.32M ﹤0.01% 2278
2022
Q2 		$3.86M Sell
198,011
-63,797
-24% -$1.24M ﹤0.01% 2462
2022
Q1 		$6.68M Sell
261,808
-6,749
-3% -$147K ﹤0.01% 2273
2021
Q4 		$6.76M Buy
268,557
+342
+0.1% +$9.64K ﹤0.01% 2308
2021
Q3 		$7.38M Buy
268,215
+35,981
+15% +$1.05M ﹤0.01% 2291
2021
Q2 		$7.37M Buy
232,234
+90,332
+64% +$3.15M ﹤0.01% 2291
2021
Q1 		$6.51M Buy
141,902
+4,493
+3% +$201K ﹤0.01% 2323
2020
Q4 		$5.44M Buy
137,409
+8,049
+6% +$318K ﹤0.01% 2317
2020
Q3 		$4.5M Buy
129,360
+73,404
+131% +$2.03M ﹤0.01% 2270
2020
Q2 		$1.77M Buy
55,956
+16,888
+43% +$531K ﹤0.01% 2757
2020
Q1 		$856K Buy
+39,068
New +$1.08M ﹤0.01% 3087

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Bank of New York Mellon's RVMD Position: Q2 2026 in Review

Bank of New York Mellon reduced its Revolution Medicines (RVMD) stake by 5.4% in Q2 2026, selling an estimated $5.01M and leaving 601,056 shares worth $113M. The position accounts for 0.02% of the portfolio, ranked #612.

Bank of New York Mellon first reported a position in RVMD in Q1 2020 and has held it in 26 quarters since. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Bank of New York Mellon held 601,056 shares of Revolution Medicines worth $113M as of Q2 2026.
  • Bank of New York Mellon sold 34,310 Revolution Medicines shares in Q2 2026, an estimated $5.01M.
  • Revolution Medicines made up 0.02% of Bank of New York Mellon's portfolio in Q2 2026, its #612 holding.
  • Bank of New York Mellon first reported a position in Revolution Medicines in Q1 2020 and has held it in 26 quarters since.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.